• Research dataclose
• Other research productsclose
• Restricted close
• ZENODO close

This record contains raw data related to article “Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab" Abstract Background and objective: Background: Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, has been recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, demonstrating a rapid onset of clinical effects. CRSwNP is characterized by an extended type-2 inflammatory involvement that can be assessed by extended nitric oxide analysis. Objective: In this study we investigated whether Dupilumab is associated with a rapid improvement in extended nitric oxide parameters, lung function and clinical outcomes in patients with CRSwNP. Methods: : Consecutive patients with CRSwNP and indication to be treated with Dupilumab were evaluated for extended nitric oxide analysis (exhaled, FENO; bronchial, JawNO and alveolar, CalvNO components; nasal, nNO) and lung function 15 and 30 days after treatment initiation, and for clinical outcomes (nasal polyps score, NPS; quality of life questionnaires; visual analogue scales, VAS, for main symptoms, asthma control test, ACT) after 30 days of treatment initiation. Results: 33 patients were enrolled. All extended nitric oxide and lung function parameters significantly improved after 15 days of treatment remaining stable at 30 days. NPS, VAS for main CRSwNP symptoms, quality of life questionnaires and ACT significantly improved after 30 days of treatment initiation. Conclusion: Dupilumab is associated with very rapid improvement in type 2 inflammation in all airway districts and this is associated with improved lung function and clinical parameters in patients with CRSwNP.

Recordings of a word list of Oy spoken in Inthii village, collected in 2018 by a colleague of Jennifer Daniell.

Experimento com mudas de Coffea arabica expostas a concentração elevada de CO2 e níveis de deficiência hídrica em Câmara de Topo Aberto.

Videos of beating heart form MRI scans

Data collected from 818 respondents who are licensed drivers in Malaysia.an online survey which was designed to assess drivers perception on advanced driver assistance systems. Questions include a demographic and driving behaviour, the perceptions of benefits and obstacles relevant to the use of advanced driver assistance systems, vehicle decision-making, and technology use.

This record contains data related to article" Direct effects of octreotide on osteoblast cell proliferation and function". Purpose. Octreotide (OCT) is a first-generation somatostatin analog (SSA) used in the treatment of acromegaly and neuroendocrine tumors (NETs). In both diseases, OCT interacts with somatostatin receptors 2 and 5 (SSTR2 and SSTR5), inhibiting hormone hypersecretion and cell proliferation. Skeletal health is an important clinical concern with acromegaly and NETs since acromegalic osteopathy and NET bone metastasis occur in a remarkable number of patients. While OCT’s effect on NET cells has been extensively investigated, its direct action on bone cells remains unknown. Methods. Here we investigated OCT direct effects on cell proliferation, differentiation, mineralization, and chemoattractant capacity of murine primary osteoblasts and osteoblast cell line MC3T3-E1. Results. OCT inhibited osteoblasts and MC3T3-E1 cell proliferation (-30% ± 16%, and -22 ± 4%, both p<0.05) and increased MC3T3-E1 cell apoptosis (+76 ± 32%, p<0.05 vs control). The anti-proliferative action of OCT was mediated by SSTR2 and SSTR5 in MC3T3-E1, while its proapoptotic effect was abrogated in SSTR2-silenced cells. The analysis of genes related to the early and late phases of osteoblast differentiation showed that OCT did not affect Alp, Runx2, Bglap, Spp1, and Sost levels in MC3T3-E1 cells. Similarly, OCT had no effect on ALP activity and mineralization in osteoblasts. In addition, Vegfa expression decreased in OCT-treated MC3T3-E1 cells and OCT inhibited pancreatic NET cell migration towards osteoblast-conditioned medium. Conclusion.This study provides the first evidence of the direct action of OCT on osteoblasts which may have clinically relevant implications for the management of skeletal health in subjects with acromegaly and metastatic NETs.

A number of studies have examined the impact of tumor stage on direct health care costs of patients with melanoma. This study aimed to investigate the association between the direct costs for melanoma and the patients’ clinical and histological characteristics. The present analysis included 1368 patients diagnosed with melanoma in 2017 in the Veneto Region (northeast Italy) and recorded in a regional population-based melanoma registry. The costs were assessed taking monthly and total direct costs into account. Log-linear multivariable analysis was used to identify the clinical and histological cost drivers, focusing on monthly and total direct costs per patient incurred during the first 2 years after a patient’s diagnosis. On multivariable analysis, besides the stage of melanoma, also the presence of mitoses (> 2) was associated with higher monthly direct costs [odds ratio (OR) 1.55, 95% confidence interval (CI) 1.15–2.08, p = 0.004] in respect to cases with 0–2 mitoses. Vertical growth was associated with higher costs compared with radial growth (OR 1.28, 95% CI 1.00–1.64, p = 0.055). Moreover, the association between the absence of tumor-infiltrating lymphocytes (TILs) and higher monthly direct costs reached statistical significance (OR 1.31, 95% CI 1.05–1.64, p = 0.017). There were no differences in monthly direct costs by patients’ sex or age, ulceration, or tumor site. This study showed that not only tumor stage but also other clinical and histopathologic characteristics have an impact on the direct monthly and total costs of treating melanoma. Further studies on the cost-effectiveness of the various options for managing this disease should take these variables into account, as well as tumor stage, as cost drivers.

Dataset contains anonymized clinical and surgical information on case reported in the related article Study received the support of Italian Ministry of Health (program RC2020)

This deposit serves as a long-term archive for the unprocessed raw data behind the uprolls2019 table in my comprehensive dataset on religion and politics in India, which is available at https://github.com/raphael-susewind/india-religion-politics/tree/master/uprolls2019

This data set includes supporting data for the manuscript "The impact of eruption source parameter uncertainties on ash dispersion forecasts during explosive volcanic eruptions" submitted to Journal of Geophysical Research - Atmospheres. The data sets consists of 3 folders: elaborated_data, NAME_simulations and REFIR_simulations. 1) elaborated_data. This folder includes data mainly used to compare eruption source parameters time series produced by REFIR in the four simulation configurations (all models, Mastin only, only wind models, only empirical models). Specifically: radar_iskef.xlsx. Time series of the Eyjafjallajokull top plume height (maximum and minimum estimate) retrieved from the C-band radar in Keflavík, Iceland. The time series is limited to the period 5/05/2010 (00:00 UTC) to 8/05/2010 (23:55 UTC). The original time series is stored in the REFIR simulation folders as radar_iskef.txt. PLH.txt. Time series f the Eyjafjallajokull top plume height (average, maximum and minimum solutions) as assessed by REFIR. cases_comparisons_FMER.txt. Time series of the final estimate of Mass Eruption Rate (FMER) for the four configurations and calculations for comparisons discussed in the manuscript. Weather_data_summary.xlsx. Time series of the weather parameters assessed by REFIR for the three estimates of the top plume heights. 2) NAME_simulations. This folders includes results (both raw data and plots) of NAME simulations for the four simulation configurations and for each estimate of the eruption source parameters (average, maximum and minimum). 3) REFIR_simulations. This folders includes input data and results (both raw data and plots) of REFIR simulations for the four simulation configurations. The input data include the original and elaborated ERA-Interim weather data for the period 5-8 May 2010 in the folder "raw_reanalysis_weather_data_20100505".